Physician
Allergy & Immunology
Dr. Thomas A. Waldmann, MD
|
|
Give Review
Thomas Waldmann practices Allergy & Immunology. He researched medicine at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He received 2 awards: "Elected Member" and "Whos Who in Medicine and Healthcare". Thomas A. Waldmann, MD is a published doctor. He has 101 publications published. The most current publication "Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2."
Publications
- Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.
- Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.
- IL-21-Driven Neoplasms in SJL Mice Mimic Some Key Features of Human Angioimmunoblastic T-Cell Lymphoma.
- Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
- Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.
- Interleukin-15 in the treatment of cancer.
- Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
- IL-15-dependent CD8(+) CD122(+) T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4(+) T cells.
- Frequent STAT5B Mutations in γδ Hepatosplenic T-cell Lymphomas.
- Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.
- The Biology of IL-15: Implications for Cancer Therapy and the Treatment of Autoimmune Disorders.
- Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα.
- Adult T-cell leukemia cells over-express Wnt5a and promote osteoclast differentiation.
- Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia.
- Markedly additive anti-tumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T cell leukemia.
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma.
- Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.
- IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T-effector memory population in peripheral blood.
- Increased serum soluble interleukin-15 receptor alpha (sIL-15R?) levels in T-cell large granular lymphocyte leukemia.
- The role of interleukin-15 in inflammation and immune responses to infection: Implications for its therapeutic use.
- Interleukin-15 biology and its therapeutic implications in cancer.
- FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
- A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.
- Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15R{alpha}.
- CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
- Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.
- Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma mo...
- Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates.
- Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities.
- Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.
- Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleu...
- Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
- Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.
- Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes.
- Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.
- Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
- Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
- Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
- EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
- Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
- Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
- IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease.
- IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells.
- Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism.
- IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.
- Receptor-directed therapy of T-cell leukemias and lymphomas.
- Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
- Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated ...
- Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.
- Colorectal carcinoma rearranges cell surface protein topology and density in CD4+ T cells.
- Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
- Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.
- A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
- The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells.
- Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
- The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia.
- ITK and IL-15 support two distinct subsets of CD8+ T cells.
- Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
- Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.
- Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
- Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
- Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene.
- Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.
- Development of antibodies and chimeric molecules for cancer immunotherapy.
- Effective cancer therapy through immunomodulation.
- Targeting the interleukin-15 system in rheumatoid arthritis.
- Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
- Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.
- Survival adjustment of mature dendritic cells by IL-15.
- Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.
- Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.
- Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
- Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation.
- IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.
- Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
- IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells.
- Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
- Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent.
- Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
- Micro-MRI methods to detect renal cysts in mice.
- IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
- Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity.
- Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
- Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells.
- A novel means of favorably tipping the balance between cytopathic and regulatory T cells.
- Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography.
- Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
- Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase.
- Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.
- Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.
- Immunotherapy: past, present and future.
- Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.
- Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent.
- The meandering 45-year odyssey of a clinical immunologist.
- IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.
- Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraaceti...
- Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
- Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates.
Schools
Harvard Medical School
Massachusetts General Hospital
Doctors Specialties
- Allergy
- Immunology
Accepted Insurances
Awards
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
Massachusetts General Hospital -
Harvard Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Dean D. Metcalfe, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Blaese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gordon D. Raphael, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dan T. Brody, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maureen Petersen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Helen C. Su, MD
This Doctor is OpenDoctor Recommended.
|